Capricor Therapeutics (CAPR) Tops Q4 EPS by 3c
Tweet
Share
E-mailGet Alerts CAPR Hot Sheet
Join SI Premium – FREE
Capricor Therapeutics (NASDAQ: CAPR) reported Q4 EPS of ($0.31), $0.03 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $9.59 thousand versus the consensus estimate of $10 thousand.
For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna shares tumble on weak full-year revenue guidance
- Jack Henry (JKHY) Tops Q4 EPS by 13c
- Eltek Ltd (ELTK) Reports Q2 EPS of $0.41
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
